“This pre-reading distribution agreement for CytoDyn`s COVID-19 clinical trials continues to underscore cytoDyn`s commitment to making leronlimab immediately available to patients based on the success of ongoing clinical trials,” said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn. “We are particularly pleased with the partnership with a company with proven expertise, unprecedented business reach and American Regent`s excellent reputation.” This agreement allows the immediate distribution of Leronlimab to patients for the treatment of COVID-19 following the successful ongoing clinical trials of CytoDyn and FDA approval Under the terms of the agreement, CytoDyn leronlimab will provide COVID-19 treatment for distribution by American Regent and will receive quarterly payments on the basis of a profit-sharing agreement. One thing that makes American Regent a perfect partner for Cytodyn is this strange section of its website dedicated to the distribution of products not authorized by the FDA! It`s definitely a perfect match. CytoDyn Inc (OTCQB:CYDY), a late-stage biotechnology company, announced Monday that it has signed an exclusive agreement with American Regent Inc. to distribute its new coronavirus (COVID-19) trial drug in the United States. Biotech CytoDyn Inc. (CYDY) has announced an exclusive sales and delivery agreement with American Regent for its Covid-19 leronlimab treatment study in the United States. Under the agreement, CytoDyn will provide leronlimab to the U.S. regent for distribution and receive quarterly payments on the basis of an incentive agreement.
American Regent is a Daiichi Sankyo Group company and an injectable manufacturer in the top 10. Although the details are few, it seems that this is an agreement with zero risk for the American Regent. As long as leronlimab has not received a UC or Covid-19 approval, there is nothing to distribute. It seems that there is no commitment, and American Regent does not receive a standard distribution supplement, but a profit sharing. The auction on leronlimab was to be intense. SARS-CoV-2 has been identified as the cause of a outbreak of respiratory diseases first detected in Wuhan, China. The origin of SARS-CoV-2, which causes COVID 19 disease, is uncertain and the virus is highly contagious. COVID-19 usually transmits person-to-person through respiratory droplets, often due to coughing, erudition and close personal contact. Coronaviruses are a large family of viruses, some of which cause diseases in humans and others that circulate among animals. Confirmed covid-19 infections, symptoms were fever, cough, and shortness of breath. Symptoms of COVID-19 can occur in just two days or up to 14 days after exposure.